Julphar launches Eltrom in Bangladesh to treat low blood platelet count in adults
Julphar Bangladesh has launched Eltrom (Eltrombopag 25 mg), the tablet used for the treatment of adult patients suffering from thrombocytopenia. Thrombocytopenia is the condition that causes unusual bruising or bleeding in patients, due to an abnormally low number of platelets in the blood.
On November 20th 2008, Eltrombopag was approved by the U.S. Food and Drug Administration (FDA) to treat thrombocytopenia in patients suffering from chronic Immune Thrombocytopenic Purpura (ITP) and who have shown an insufficient response to corticosteroids, immunoglobulin therapy or splenectomy. It has received the FDA breakthrough treatment designation in February 2014 for patients with aplastic anemia for which immunosuppression has not been successful.
“The launch of Eltrom in Bangladesh is part of our commitment to introduce the latest molecules to the market”, said Sudhir K Sinha, Managing Director at Julphar Bangladesh. “Through relentless efforts, our team is contributing to the improvement of patients’ quality of life in the country, and we will keep on supporting the healthcare community by providing high quality, affordable medicines to all.”